DexCom gains as investors appear to welcome earnings momentum and growth outlook

DexCom (DXCM) is up 9.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is DexCom’s second-quarter 2026 earnings release, which was scheduled for July 30 after the close, with investors seemingly responding to continued confidence in revenue growth, margin improvement, and the company’s expanding continuous glucose monitoring platform. While full market consensus comparisons were not clearly available in the materials reviewed, the move suggests traders viewed the update as better than feared or supportive of the company’s growth narrative.

Details:

DexCom had already told investors it would release second-quarter 2026 financial results on July 30, making the earnings event the clearest near-term driver of today’s move.

In its first-quarter 2026 report, the company posted 15% year-over-year revenue growth to $1.192 billion, with U.S. revenue up 11% and international revenue up 26%, while also lifting its profitability outlook for 2026.

Management had pointed to healthy demand for Dexcom CGM products, expanded rollout of the G7 15 Day system, and improvements to the Stelo platform, all of which may have reinforced confidence heading into the quarter.

Recent clinical and strategic updates, including new data supporting CGM use in people with type 2 diabetes not using insulin and the company’s push toward broader metabolic health offerings, may also have supported bullish sentiment.

Sources:

DexCom, SEC, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DXCM Insider Trading Activity

$DXCM insiders have traded $DXCM stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:

KEVIN R SAYER (Executive Chair) has made 0 purchases and 3 sales selling 80,271 shares for an estimated $5,895,079.
JON COLEMAN (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 9,823 shares for an estimated $722,628.
MICHAEL JON BROWN (EVP Chief Legal Compliance Off) has made 0 purchases and 5 sales selling 8,500 shares for an estimated $574,209.
MARK G FOLETTA has made 0 purchases and 2 sales selling 4,000 shares for an estimated $296,539.
BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $129,556.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DXCM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DXCM Hedge Fund Activity

We have seen 466 institutional investors add shares of $DXCM stock to their portfolio, and 412 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 6,252,665 shares (+203.4%) to their portfolio in Q1 2026, for an estimated $392,667,362
JENNISON ASSOCIATES LLC removed 4,741,847 shares (-81.9%) from their portfolio in Q1 2026, for an estimated $297,787,991
ALLIANCEBERNSTEIN L.P. added 4,299,512 shares (+49.9%) to their portfolio in Q1 2026, for an estimated $270,009,353
NUVEEN, LLC removed 2,907,804 shares (-62.8%) from their portfolio in Q1 2026, for an estimated $182,610,091
UBS GROUP AG added 2,426,179 shares (+126.1%) to their portfolio in Q1 2026, for an estimated $152,364,041
TORONTO DOMINION BANK added 2,237,087 shares (+980.0%) to their portfolio in Q1 2026, for an estimated $140,489,063
CITADEL ADVISORS LLC added 2,004,972 shares (+2307.2%) to their portfolio in Q1 2026, for an estimated $125,912,241

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DXCM Congressional Stock Trading

Members of Congress have traded $DXCM stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:

SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DXCM Analyst Ratings

Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/13/2026

To track analyst ratings and price targets for $DXCM, check out Quiver Quantitative's $DXCM forecast page.

$DXCM Price Targets

Multiple analysts have issued price targets for $DXCM recently. We have seen 12 analysts offer price targets for $DXCM in the last 6 months, with a median target of $85.0.

Here are some recent targets:

Kieran Ryan from Deutsche Bank set a target price of $86.0 on 06/23/2026
Matt O'Brien from Piper Sandler set a target price of $88.0 on 06/15/2026
Joshua Jennings from TD Cowen set a target price of $95.0 on 06/10/2026
Anthony Petrone from Mizuho set a target price of $85.0 on 06/09/2026
Jonathan Block from Stifel set a target price of $90.0 on 06/05/2026
Joanne Wuensch from Citigroup set a target price of $84.0 on 05/28/2026
Matt Miksic from Barclays set a target price of $64.0 on 05/18/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.